Brian I. Rini

Brian I. Rini's AcademicInfluence.com Rankings

Brian I. Rini

Philosophy

#3707

World Rank

#5936

Historical Rank

Logic

#1345

World Rank

#2071

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Brian I. Rini's Degrees

Bachelors Biological Sciences Stanford University

Why Is Brian I. Rini Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Brian I. Rini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1808)
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) (1682)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (2011) (1656)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) (1646)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1425)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
Sunitinib in patients with metastatic renal cell carcinoma. (2006) (965)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (934)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. (2015) (926)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009) (832)
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010) (759)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. (2013) (723)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (2016) (703)
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. (2008) (687)
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. (2013) (636)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019) (611)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011) (570)
Resistance to targeted therapy in renal-cell carcinoma. (2009) (517)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). (2004) (512)
Renal cell carcinoma (2009) (498)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (479)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
Treatment of renal cell carcinoma: Current status and future directions (2017) (472)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. (2007) (433)
Renal cell carcinoma (2007) (419)
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. (2005) (404)
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. (2010) (403)
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer (2007) (396)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. (2008) (395)
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. (2013) (394)
Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. (2015) (387)
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2014) (379)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. (2007) (378)
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. (2017) (334)
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. (2009) (328)
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. (2011) (328)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins (2007) (321)
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. (2011) (303)
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. (2015) (286)
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. (2010) (284)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (2020) (276)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. (2017) (261)
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. (2011) (258)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2014) (253)
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. (2009) (252)
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. (2008) (237)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020) (234)
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. (2013) (230)
Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2007) (225)
HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism (2017) (224)
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. (2010) (218)
A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. (2015) (215)
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. (2014) (202)
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. (2014) (202)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. (2018) (201)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. (2017) (194)
IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) (2018) (189)
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria (2013) (182)
Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors (2011) (179)
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) (178)
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. (2009) (178)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. (2016) (176)
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. (2009) (175)
HIF Inhibitors: Status of Current Clinical Development (2019) (174)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. (2020) (173)
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2014) (171)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2016) (169)
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. (2002) (168)
Renal Angiomyolipoma: Clinicopathologic Study of 194 Cases With Emphasis on the Epithelioid Histology and Tuberous Sclerosis Association (2009) (167)
Recent Progress in the Management of Advanced Renal Cell Carcinoma (2007) (165)
AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) (2005) (163)
Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma (2011) (162)
COVID-19 and Cancer: Current Challenges and Perspectives (2020) (160)
Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions (2007) (159)
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. (2008) (159)
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. (2019) (158)
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (2019) (158)
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. (2016) (156)
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin (2008) (152)
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. (2000) (150)
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. (2016) (150)
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. (2016) (148)
Cancer and Leukemia Group B 90206 (2004) (147)
State of the Science: An Update on Renal Cell Carcinoma (2012) (146)
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. (2008) (144)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2018) (141)
Sunitinib facilitates the activation and recruitment of therapeutic anti‐tumor immunity in concert with specific vaccination (2011) (140)
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma (2018) (140)
The von Hippel–Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C (2012) (136)
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. (2016) (135)
Surgical resection of renal cell carcinoma after targeted therapy. (2009) (130)
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma (2013) (130)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy (2006) (129)
Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis (2013) (128)
Sunitinib rechallenge in metastatic renal cell carcinoma patients (2010) (128)
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. (2011) (127)
Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. (2014) (126)
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib (2012) (126)
Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) (2005) (124)
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. (2014) (122)
Metastatic renal cell carcinoma: many treatment options, one patient. (2009) (122)
The immunology of renal cell carcinoma (2020) (121)
A high rate of venous thromboembolism in a multi‐institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma (2002) (117)
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. (2011) (117)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α (2016) (116)
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. (2019) (114)
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. (2014) (113)
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. (2012) (111)
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma (2020) (109)
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study (2020) (107)
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status (2006) (107)
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney (2012) (106)
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial (2014) (102)
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. (2003) (97)
Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. (2011) (92)
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. (2004) (91)
CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (2017) (90)
Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). (2008) (87)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (87)
New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance (2010) (86)
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients (2015) (84)
Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib (2007) (83)
Vascular endothelial growth factor‐targeted therapy in metastatic renal cell carcinoma (2009) (83)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. (2019) (82)
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. (2012) (81)
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. (2019) (81)
Prospective Clinical Study of Precision Oncology in Solid Tumors. (2015) (81)
Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy (2011) (81)
The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. (2007) (79)
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2015) (79)
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. (2016) (79)
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. (2004) (79)
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma (2019) (78)
A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab (2008) (77)
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages (2021) (77)
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. (2005) (76)
CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. (2019) (76)
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2015) (75)
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (2019) (75)
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. (2010) (75)
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. (2015) (75)
Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial (2020) (74)
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. (2014) (74)
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. (2008) (74)
Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity: Molecular and Histologic Evidence (2009) (73)
Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. (2014) (72)
Erratum: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial (Lancet (2011) 378 (1931-39)) (2012) (72)
Prostate cancer update (2002) (72)
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. (2015) (72)
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (2014) (71)
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. (2015) (71)
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis (2007) (68)
Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). (2018) (68)
Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial (2020) (67)
VEGF-targeted therapy in metastatic renal cell carcinoma. (2005) (67)
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab (2010) (67)
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. (2013) (67)
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. (2014) (66)
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (2016) (66)
A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (2009) (66)
Hormone-Refractory prostate cancer (2002) (66)
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC (2014) (65)
Metabolism of kidney cancer: from the lab to clinical practice. (2013) (64)
Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2017) (64)
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
Molecular Biomarkers in Advanced Renal Cell Carcinoma (2014) (62)
A phase II study of gemcitabine and capecitabine in metastatic renal cancer (2006) (62)
Maximal COX‐2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma (2006) (62)
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial (2013) (61)
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2016) (61)
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. (2005) (61)
Renal cell carcinoma (2005) (60)
Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2010) (60)
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy (2006) (60)
Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). (2006) (60)
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (2019) (59)
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. (2009) (59)
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review (2019) (58)
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? (2012) (58)
Targeted molecular therapy for renal cell carcinoma. (2007) (58)
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. (2016) (57)
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. (2016) (56)
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. (2020) (55)
From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. (2019) (54)
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (2006) (54)
GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. (2009) (54)
Castration‐resistant prostate cancer: Many treatments, many options, many challenges ahead (2012) (53)
Novel agents in renal carcinoma: a reality check (2012) (53)
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development (2005) (53)
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab (2018) (52)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021) (52)
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (2020) (51)
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). (2009) (50)
Elevated Levels of Select Gangliosides in T Cells from Renal Cell Carcinoma Patients Is Associated with T Cell Dysfunction1 (2009) (50)
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma (2013) (50)
Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. (2015) (50)
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. (2011) (49)
COVID-19 and immune checkpoint inhibitors: initial considerations (2020) (49)
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (2018) (49)
CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (2015) (48)
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. (2013) (48)
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. (2012) (48)
Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution (2016) (47)
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial (2014) (47)
Prognostic factors in renal carcinoma. (2000) (46)
Pancreatic tropism of metastatic renal cell carcinoma. (2020) (46)
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients (2013) (46)
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. (2020) (46)
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. (2015) (45)
Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. (2018) (45)
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib (2018) (44)
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma (2022) (44)
Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers (2007) (44)
Technology evaluation: APC-8015, Dendreon. (2002) (44)
Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. (1999) (43)
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. (2019) (43)
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. (2020) (43)
Renal cell carcinoma (2006) (43)
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma (2009) (43)
Prostate cancer immunology: biology, therapeutics, and challenges. (2005) (42)
Axitinib for renal cell carcinoma (2008) (42)
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. (2010) (42)
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. (2019) (41)
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target (2018) (41)
Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma (2014) (41)
Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma (2007) (41)
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. (2021) (41)
First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. (2017) (41)
Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone (2008) (41)
AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. (2011) (40)
Randomized Phase IIIB Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from Intoract (2012) (40)
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience (2005) (40)
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape (2012) (39)
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. (2018) (39)
Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. (2012) (39)
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. (2006) (39)
[Breast cancer in the early stage]. (2012) (39)
Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma (2008) (39)
JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). (2018) (39)
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. (2006) (39)
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. (2020) (38)
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group (2018) (38)
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer (2020) (38)
Current Treatment Considerations in Metastatic Renal Cell Carcinoma (2012) (38)
Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. (2006) (38)
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. (2020) (38)
Molecularly targeted therapy in renal cell carcinoma (2005) (38)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. (2009) (37)
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. (2015) (37)
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. (2016) (37)
Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. (2019) (37)
Signal Integration and Gene Induction by a Functionally Distinct STAT3 Phosphoform (2014) (36)
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). (2017) (36)
Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. (2006) (35)
A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. (2017) (35)
Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma (2013) (35)
Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. (2006) (34)
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma (2011) (34)
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma (2018) (34)
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial (2022) (34)
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. (2007) (33)
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. (2008) (33)
Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. (2019) (32)
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. (2001) (32)
Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer (2017) (32)
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer (2020) (32)
Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy. (2014) (32)
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. (2007) (32)
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. (2019) (32)
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma (2016) (31)
Genitourinary tumors, non-prostate (2012) (31)
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response. (2021) (31)
Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery (2018) (31)
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. (2007) (31)
Adjuvant therapy in renal cell carcinoma (2019) (31)
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. (2010) (30)
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. (2018) (30)
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. (2015) (30)
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model (2016) (30)
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor (2016) (29)
Granulocyte‐macrophage‐colony stimulating factor in metastatic renal cell carcinoma (1998) (29)
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. (2021) (29)
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. (2014) (29)
Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy. (2011) (29)
Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. (2012) (29)
Immunotherapy for metastatic renal cell carcinoma (2007) (29)
Axitinib for renal cell carcinoma. (2008) (28)
Management of the small renal mass (2017) (28)
Noncytotoxic differentiation treatment of renal cell cancer. (2011) (28)
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib (2011) (27)
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting (2020) (26)
Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer (2016) (26)
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. (2013) (26)
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events (2020) (26)
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. (2015) (26)
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells (2004) (25)
17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC (2015) (25)
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. (2021) (25)
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC). (2010) (25)
Differential expression of caveolin‐1 in renal neoplasms (2007) (25)
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma (2020) (25)
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). (2013) (25)
Future approaches in immunotherapy. (2014) (25)
Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC) (2007) (25)
The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. (2010) (24)
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy (2012) (24)
Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). (2005) (24)
Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib (2007) (24)
661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) (2021) (24)
Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma (2012) (24)
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial (2021) (24)
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. (2014) (24)
Feasibility of Cisplatin‐Based Neoadjuvant Chemotherapy in Muscle‐Invasive Bladder Cancer Patients With Diminished Renal Function (2018) (23)
1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (23)
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens (2018) (23)
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 (2021) (23)
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis (2020) (23)
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma (2018) (23)
Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs (2019) (23)
Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial (2011) (23)
Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma. (2016) (23)
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma (2015) (23)
Pazopanib for the treatment of renal cancer (2011) (22)
Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma (2016) (22)
A genomic algorithm for the molecular classification of common renal cortical neoplasms: development and validation. (2015) (22)
A Phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma (2005) (22)
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. (2015) (22)
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse (2021) (22)
Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. (2009) (22)
7103 ORAL Association of Single Nucleotide Polymorphisms (SNPs) in VEGF Pathway Genes With Progression-free Survival (PFS) and Blood Pressure (BP) in Metastatic Renal Cell Carcinoma (mRCC) in the Phase 3 Trial of Axitinib Versus Sorafenib (AXIS Trial) (2011) (22)
Flt-3 Ligand and Sequential FL/Interleukin-2 in Patients With Metastatic Renal Carcinoma: Clinical and Biologic Activity (2002) (21)
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (21)
Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. (2009) (21)
Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). (2011) (21)
Emerging therapeutic approaches in renal cell carcinoma (2015) (20)
Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma. (2014) (20)
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma (2016) (20)
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy (2019) (20)
A Modern Assessment of Cancer Risk in Adrenal Incidentalomas (2020) (20)
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. (2019) (20)
Current status and future directions of molecular markers in renal cell carcinoma (2006) (20)
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN‐01, in renal cell carcinoma (2004) (19)
Dual VEGF/VEGFR inhibition in advanced solid malignancies (2014) (19)
711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy (2020) (19)
Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). (2017) (19)
Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma (2018) (19)
Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? (2008) (19)
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma (2017) (19)
A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (19)
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010) (2017) (19)
Sunitinib and bevacizumab in advanced solid tumors: A phase I trial (2008) (19)
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. (2021) (18)
COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors (2021) (18)
Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma (2006) (18)
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib (2016) (18)
1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (18)
Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): Safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy (2008) (18)
Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma (2012) (18)
A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (18)
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19). (2020) (18)
Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. (2011) (18)
A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). (2014) (17)
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports. (2006) (17)
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study (2016) (17)
A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. (2010) (17)
Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). (2010) (17)
The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). (2011) (16)
IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (2011) (16)
SU11248 and AG013736: current data and future trials in renal cell carcinoma. (2005) (16)
Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study (2016) (16)
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19 (2021) (16)
A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. (2012) (16)
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. (2018) (16)
Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. (2017) (16)
Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study (2017) (16)
Correction: A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (2009) (16)
A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. (2006) (16)
The potential for prostate cancer immunotherapy. (2003) (16)
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma (2020) (16)
Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. (2020) (16)
Long‐Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials (2017) (16)
Emerging therapeutics in refractory renal cell carcinoma (2016) (16)
External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. (2011) (16)
Emerging immunotherapy in advanced renal cell carcinoma. (2017) (15)
A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. (2014) (15)
Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma (2018) (15)
MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma (2019) (15)
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone (2013) (15)
Severity of illness scores at presentation predict ICU admission and mortality in COVID-19 (2021) (15)
Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (15)
Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma. (2016) (15)
Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). (2016) (15)
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. (2020) (15)
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma (2019) (15)
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). (2019) (15)
Clinical and Immunomodulatory Effects of Celecoxib Plus Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients with COX-2 Tumor Immunostaining (2011) (15)
Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma (2016) (14)
2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC) (2015) (14)
Maximizing clinical outcomes with axitinib therapy in advanced renal cell carcinoma through proactive side-effect management (2012) (14)
Perinephric and Sinus Fat Invasion in Stage pT3a Tumors Managed by Partial Nephrectomy (2017) (14)
Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC). (2017) (14)
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) (2015) (14)
Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors (2012) (14)
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma (2012) (14)
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). (2015) (14)
Cancer Immunotherapy Principles and Practice (2018) (13)
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial (2022) (13)
Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases (2007) (13)
Biomarkers: hypertension following anti-angiogenesis therapy. (2010) (13)
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial (2021) (13)
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies (2018) (13)
Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. (2020) (13)
Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. (2019) (13)
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. (2017) (13)
VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices (2006) (13)
Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: Balancing the expansion of activated effector and regulatory T cells (2007) (13)
A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors (2007) (13)
LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) (2020) (13)
Quantifying hypertension in patients with cancer treated with sorafenib. (2008) (13)
Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma (2015) (12)
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma (2020) (12)
Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. (2019) (12)
Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinoma (2012) (12)
Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC) (2012) (12)
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. (2019) (12)
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. (2014) (12)
Discontinuing VEGF‐targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second‐line Therapies in Metastatic Renal Cell Carcinoma (2017) (12)
The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma (2016) (12)
Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214. (2019) (12)
Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2014) (12)
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (2018) (12)
Care without a compass: Including patients with cancer in COVID-19 studies (2021) (12)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1b, IL8, CXCL5, and Mip-1a (2017) (12)
Drug Holiday in Metastatic Renal‐Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors (2018) (11)
Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma. (2006) (11)
Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors. (2018) (11)
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. (2015) (11)
Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients (2017) (11)
4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib (2007) (11)
Individualized dosing with axitinib: rationale and practical guidance. (2018) (11)
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) (2017) (11)
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations (2020) (11)
Sunitinib in patients (pts) with unresectable primary renal cell carcinoma (RCC). (2016) (11)
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. (2008) (11)
Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis. (2017) (11)
Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma (2020) (11)
Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer (2020) (11)
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. (2019) (11)
Integration of surgery and systemic therapy in the management of metastatic renal cancer (2009) (11)
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. (2016) (11)
Phase I/II trial of GM-CSF and lenalidomide in patients with hormone refractory prostate cancer (HRPC) (2007) (11)
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. (2014) (11)
Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib (2006) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. (2016) (10)
Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer. (2018) (10)
Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. (2018) (10)
Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) (2020) (10)
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma (2020) (10)
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. (2021) (10)
Granulocyte-Macrophage-Colony Stimulating Factor in Metastatic Renal Cell Carcinoma. A Phase II Trial (1999) (10)
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (2021) (10)
Targeted therapy for patients with renal-cell carcinoma. (2011) (10)
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). (2012) (9)
Determining the optimal dose and schedule of sunitinib (2012) (9)
The ineligible patient: how to treat patients not included in clinical studies (2014) (9)
Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. (2014) (9)
Immunotherapy for renal cell carcinoma (2019) (9)
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma. (2013) (9)
Recent clinical development of dendritic cell-based immunotherapy for prostate cancer (2004) (9)
TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2019) (9)
Sunitinib (2007) (9)
The HLA‐A2‐restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer (2009) (9)
Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 (2019) (9)
Imaging strategy and outcome following partial nephrectomy. (2017) (9)
Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (2010) (9)
Treatment selection for men with metastatic prostate cancer who progress on upfront chemo‐hormonal therapy (2018) (9)
Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis (2017) (9)
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). (2014) (9)
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study (2021) (9)
An update on prostate cancer (2001) (9)
Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2009) (9)
Future Challenges for Drug Development in Renal Cell Carcinoma. (2017) (8)
Urinary Biomarkers for the Detection and Management of Localized Renal Cell Carcinoma. (2015) (8)
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports (2020) (8)
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
Axitinib in Metastatic Renal Cell Carcinoma (2012) (8)
A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma (2018) (8)
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. (2022) (8)
Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium. (2015) (8)
Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies (2019) (8)
Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model (2015) (8)
Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. (2020) (8)
Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib. (2011) (8)
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop. (2019) (8)
Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. (2017) (8)
Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities (2008) (8)
The use of sunitinib in renal cell carcinoma: where are we now? (2014) (8)
Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. (2021) (8)
Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. (2018) (8)
Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS). (2021) (8)
The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium. (2014) (8)
New approaches in advanced renal cell carcinoma. (2005) (8)
Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC). (2019) (8)
Emerging drugs for renal cell carcinoma (2010) (8)
Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib (2008) (8)
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. (2014) (8)
Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma (2016) (7)
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2017) (7)
Phase III AXIS trial of axitinib versus sorafenib in metastatic renal cell carcinoma: Updated results among cytokine-treated patients. (2012) (7)
Erratum: Pazopanib for the treatment of renal cancer (Expert Opin Pharmacother (2011) 12: 7 (1171-1189)) (2011) (7)
Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) (2016) (7)
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial (2021) (7)
Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. (2021) (7)
Practice and progress in kidney cancer: methodology for novel drug development. (2004) (7)
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab (2021) (7)
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma (2021) (7)
Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? (2009) (7)
Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). (2016) (7)
Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214). (2018) (7)
Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC). (2019) (7)
Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. (2020) (7)
Sorafenib (2006) (6)
GM 1 and Tumor Necrosis Factor-A , Overexpressed in Renal Cell Carcinoma , Synergize to Induce T-Cell Apoptosis (2008) (6)
To Treat or Not to Treat-Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. (2020) (6)
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. (2021) (6)
Specific immunotherapy in renal cancer: a systematic review (2017) (6)
Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population. (2011) (6)
The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma (2007) (6)
Seminar article Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma (2008) (6)
Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy (2007) (6)
Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia. (2006) (6)
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients (2016) (6)
Renal cell carcinoma: Clinical management (2013) (6)
Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (6)
Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study. (2021) (6)
A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC) (2007) (6)
A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. (2012) (6)
Hereditary implications of somatic tumor testing. (2015) (6)
Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S). (2020) (6)
Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. (2017) (6)
Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens. (2018) (6)
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. (2021) (6)
Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). (2020) (6)
Is sorafenib plus interferon α2b safe and effective in patients with renal cell carcinoma? (2008) (6)
Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. (2020) (6)
The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics (2007) (5)
American Society for Clinical Pharmacology and Therapeutics (2023) (5)
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma (2017) (5)
A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (2008) (5)
Axitinib for the treatment of metastatic renal cell carcinoma. (2016) (5)
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. (2016) (5)
Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). (2015) (5)
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma (2022) (5)
Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy. (2011) (5)
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study (2019) (5)
Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry (2020) (5)
Holland - Frei Manual Of Cancer Medicine (2005) (5)
810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (5)
The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC). (2015) (5)
Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma (2022) (5)
Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (5)
Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma (2018) (5)
Metastatic renal cell carcinoma (mRCC) patients (pts) with sarcomatoid features treated with VEGF-targeted therapy (2008) (5)
Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach (2021) (5)
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma (2011) (4)
Renal cell carcinoma: ten years of significant advances (2010) (4)
Kidney cancer in 2012: New frontiers in kidney cancer research (2013) (4)
Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. (2022) (4)
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2017) (4)
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes (2018) (4)
LBA39IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) (2017) (4)
Renal Cell Carcinoma (2012) (4)
Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study. (2017) (4)
WBC changes as a pharmacodynamic marker of outcome in metastatic renal cell carcinoma (mRCC) patients (Pts) receiving sunitinib (2007) (4)
TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). (2020) (4)
Radical shifts in the first-line management of metastatic renal cell carcinoma (2018) (4)
Long term toxicity of tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC) (2008) (4)
3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC) (2011) (4)
Sunitinib's effect on tumor infiltration of CD8 T cells in renal cell carcinoma (RCC) and modulation of their function by altering VEGF-induced upregulation of PD1 expression. (2016) (4)
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma (2017) (4)
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2016) (4)
A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). (2014) (4)
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. (2021) (4)
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts (2020) (4)
Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis (2017) (4)
Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC). (2016) (4)
Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. (2013) (4)
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2019) (4)
Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101 (2022) (4)
4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers (2007) (4)
Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. (2010) (4)
Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study. (2017) (4)
Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. (2020) (4)
Targeted therapy in renal cell carcinoma (2008) (4)
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply. (2019) (4)
Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). (2013) (4)
Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001). (2022) (4)
CTLA-4 blockade-based immunotherapy for prostate cancer. (2004) (4)
Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
Kidney cancer: Does hypothyroidism predict clinical outcome? (2011) (4)
Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology? (2016) (4)
On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis? (2017) (4)
Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC). (2018) (4)
Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) (2016) (4)
Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma (2005) (4)
501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial (2015) (4)
Neurophysiological changes: Sunitinib fatigue severity. (2016) (3)
Impact of the USPSTF recommendations on prostate cancer stage migration and de-novo metastatic prostate cancer. (2019) (3)
Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF). (2019) (3)
Expression of FLT3 and VEGFR1 on myeloid derived suppressor cells (MDSC) in renal cell carcinoma (RCC) patients (Pts) (2008) (3)
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma (2020) (3)
Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus (2008) (3)
What is standard initial systemic therapy in metastatic renal cell carcinoma? (2007) (3)
Uncommon Tumors of the Kidney (2012) (3)
Accumulation of tumor infiltrating myeloid-derived suppressor cells associates with changes in the immune landscape of clear cell renal cell carcinoma. (2018) (3)
Dissecting responsive phenotypes through cytokine and angiogenic factor analysis. (2012) (3)
Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC). (2006) (3)
Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. (2015) (3)
Emerging Targets in Clear Cell Renal Cell Carcinoma (2022) (3)
Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (2015) (3)
The Context of Blood Vessels and Response to VEGF-Targeted Therapy (2013) (3)
Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression (2016) (3)
A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). (2021) (3)
81 Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) (2012) (3)
Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2014) (3)
Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214. (2019) (3)
Clinical trials in patients with biochemically relapsed prostate cancer (2006) (3)
Serial measurements of myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint inhibitors (CI). (2017) (3)
Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101. (2020) (3)
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. (2018) (3)
Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype. (2017) (3)
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab (2021) (3)
Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma. (2015) (3)
Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) (2021) (3)
A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts. (2014) (3)
Abstract 2372: Capture and molecular characterization of CTC in metastatic breast, prostate, colorectal, and renal cancer (2012) (3)
Targeting the VEGF Pathway in Renal Cell Carcinoma (2012) (3)
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma (2022) (3)
State-ofthe-science : An update on renal cell carcinoma (2012) (3)
Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib. (2014) (3)
Accumulation of MDSC subsets in renal cell carcinoma correlates with grade and progression free survival, and is associated with intratumoral expression of IL-1β, IL-8 and CXCL5 (2014) (3)
CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study. (2004) (3)
Correlation between gene expression and prognostic biomarkers in small cell bladder cancer (SCBC). (2018) (3)
Angiogenesis Inhibitor Therapy in Renal Cell Cancer (2012) (2)
Biology and treatment of advanced renal cell carcinoma: a global perspective. (2013) (2)
A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab. (2020) (2)
Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. (2021) (2)
Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience (2004) (2)
Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. (2012) (2)
First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. (2022) (2)
Can patient-reported kidney cancer–specific symptoms at baseline serve as an indicator for median progression-free and overall survival in sorafenib-refractory metastatic renal cell carcinoma? (2010) (2)
An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy. (2012) (2)
Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States. (2014) (2)
Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. (2022) (2)
Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery. (2017) (2)
Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint? (2015) (2)
Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial. (2018) (2)
417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma (2021) (2)
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). (2019) (2)
Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. (2014) (2)
7154 An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy (2009) (2)
Circulating tumor cell kinetics in mRCC patients treated with sunitinib (2014) (2)
HSD3B1 genotype and abiraterone (Abi) metabolites in patients (pts) with prostate cancer (PCa). (2018) (2)
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. (2021) (2)
Treatment of Refractory Metastatic Renal Cell Carcinoma (2022) (2)
Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone (2020) (2)
Comprar Renal Cell Carcinoma | Brian I. Rini | 9781607950035 | Mcgraw-Hill Education (2009) (2)
669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study (2021) (2)
First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC). (2013) (2)
Lapatinib therapy for patients with advanced renal cell carcinoma (2008) (2)
Molecularly targeted therapy in renal cell carcinoma: where do we go from here? (2006) (2)
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (2022) (2)
Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy (2012) (2)
Malignant angiomyolipoma: a rare entity with unusual biology. (2011) (2)
What Is Standard Initials Systemic Therapy in Metastatic Renal Cell Carcinoma (2007) (2)
What are the prognostic factors for survival in patients with metastatic renal cell carcinoma? (2005) (2)
A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC). (2020) (2)
TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC). (2021) (2)
The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. (2016) (2)
DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1. (2015) (2)
354 Phase I study of investigational oral mTORC1/2 inhibitor MLN0128: Expansion phase in patients with renal, endometrial, or bladder cancer (2015) (2)
The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases. (2012) (2)
Adjuvant enzalutamide (Enza) for men with non-metastatic high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). (2018) (2)
Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). (2016) (2)
502: Effect of Sunitinib in Patients with Unresectable Primary Renal Cell Carcinoma (2007) (2)
Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101. (2021) (2)
Update on the use of mTOR inhibitors in renal cell carcinoma. (2008) (2)
A phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at high risk of recurrence following resection (IMmotion010) (2018) (2)
Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). (2017) (2)
Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) (2017) (1)
Biomarkers of response to VEGF pathway-targeted therapy for renal cell carcinoma. (2006) (1)
Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC). (2021) (1)
Renal cell carcinoma. (2007) (1)
Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC. (2021) (1)
Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice. (2017) (1)
Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors? (2021) (1)
An alternative titration schedule of axitinib in metastatic renal cell carcinoma. (2015) (1)
The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases. (2012) (1)
Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP). (2016) (1)
Erratum (2011) (1)
4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial (2015) (1)
Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium. (2012) (1)
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. (2014) (1)
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC). (2019) (1)
Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma. (2015) (1)
Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma. (2019) (1)
Practice challenges affecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas. (2014) (1)
Cessation of VEGF-targeted therapy in patients with metastatic renal cell carcinoma (mRCC): Feasibility and clinical outcome. (2011) (1)
Prior estrogen therapy as a predictor of response to subsequent estramustine-based therapy in androgen-independent prostate cancer patients. (2004) (1)
Unclassified renal cell carcinoma (RCC): Analysis of clinical and pathologic features (2008) (1)
PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC). (2022) (1)
Assessment of sarcopenia as predictor of response and outcome after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). (2015) (1)
Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). (2017) (1)
Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011) (1)
Abstract 630: Interleukin-8 as a potential mediator for renal cell carcinoma resistance to antiangiogenic sunitinib therapy (2010) (1)
Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2007) (1)
Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? (2015) (1)
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma. (2017) (1)
SUNITINIB MALATE (SU11248) – EFFICACY IN RENAL CELL CARCINOMA (RCC) (2006) (1)
Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium. (2016) (1)
The mechanism of action and resistance of sunitinib in RCC. (2010) (1)
Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's) (2007) (1)
A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma. (2017) (1)
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. (2014) (1)
Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more (2017) (1)
First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC). (2013) (1)
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). (2012) (1)
Robotic partial nephrectomy after pazopanib treatment in a solitary kidney with segmental vein thrombosis (2019) (1)
Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. (2023) (1)
MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study. (2021) (1)
The myeloid receptor TREM2 exacerbates DSS-induced colitis and promotes colitis-associated cancer (TUM4P.916) (2014) (1)
The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue. (2018) (1)
200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia (2020) (1)
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma (2022) (1)
The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. (2016) (1)
PD2-3 Towards Optimal Management of Metastatic Renal Cell Carcinoma : an Update on the Role of Sunitinib as First-line Treatment (2008) (1)
Patients with Hormone-Refractory Prostate Cancer A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Updated (2007) (1)
Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation. (2017) (1)
Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC). (2016) (1)
MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE) (2015) (1)
Erratum to "B.I. Rini, E.J. Small, The potential for prostate cancer immunotherapy" (Crit. Rev. Oncol./Hematol. 46 (2003) S117-S127) (2012) (1)
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group. (2017) (1)
Recent advances in molecularly targeted therapy in advanced renal cell carcinoma (2009) (1)
The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC). (2015) (1)
Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma (2019) (1)
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). (2022) (1)
B7H1 expression and association with clinical response to sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC). (2013) (1)
Discrepancy between reported progressive disease per radiology report and treating oncologist tumor measurements in patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib. (2012) (1)
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 (2022) (1)
Sunitinib ReversesType-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients (2008) (1)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
843PLONG-TERM SAFETY WITH AXITINIB IN ADVANCED RENAL CELL CARCINOMA. (2014) (1)
717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) (2021) (1)
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (1)
Evaluation of patient (Pt), treatment, and prognostic factors in urinary tract adenocarcinoma. (2017) (1)
Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study (2021) (1)
Abstract 2539: CTLA-4 blockade for hormone refractory prostate cancer: Dose-dependent induction of CD8+ T cell activation and clinical responses (2008) (1)
Effect of pazopanib on myeloid-derived suppressor cells and T-cell function in patients with metastatic renal cell carcinoma. (2013) (1)
Detection of circulating tumor cells in advanced renal cell carcinoma patients using microfilter-based capture (2012) (1)
TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2019) (1)
Abstract 3520: PBRM1 inactivation in renal cell cancer alters master transcription factor hub composition to repress instead of activate epithelial-differentiation (2017) (1)
Association of PD-1 and PD-L1 protein expression in matched primary and metastatic renal cell carcinoma tumors. (2015) (1)
Abstract 5365: Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide (2012) (1)
A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma. (2012) (1)
Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. (2018) (1)
Abstract 4378: Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma (2012) (1)
Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC). (2019) (1)
Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. (2018) (1)
Issue information (2013) (0)
Modulation of Immune Effector and Regulator Cells by Sunitinib: Potential for Combination Therapy in Renal Cell Carcinoma Patients (2012) (0)
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma (2015) (0)
Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways. (2013) (0)
Toward individualized treatment in urologic oncology. (2015) (0)
Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC). (2011) (0)
Association between primary tumor protein expression and response to sunitinib in patients with metastatic renal cell carcinoma. (2015) (0)
Clinical Study Phase 1 study of mTORC 1 / 2 inhibitor sapanisertib ( TAK-228 ) in advanced solid tumours , with an expansion phase in renal , endometrial or bladder cancer (0)
Resistance through Understanding the Molecular Basis of Response and New Strategies in Kidney Cancer : Therapeutic Advances (2010) (0)
HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC). (2022) (0)
The Rapidly Evolving Landscape of Immunotherapy in RCC (2018) (0)
Circulating cell-free DNA (cfDNA) levels and fragmentation pattern can distinguish nonmuscle invasive (NMI) from muscle-invasive (MI) and metastatic (met) bladder cancer (BC). (2019) (0)
A phase II trial of ketoconazole plus granulocyte/macrophage-colony stimulating factor (GM-CSF) in androgen independent prostate cancer (AIPC) patients (pts) (2005) (0)
Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB). (2018) (0)
Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery. (2018) (0)
Practice challenges afecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas (2014) (0)
Nonsystemic Approaches to the Management of Metastatic Renal Cell Carcinoma (2011) (0)
731 Concurrent immunotherapy and dipeptidyl peptidase-4 inhibition among patients with solid tumors (2021) (0)
Erratum: "Axitinib for renal cell carcinoma" (Expert Opinion on Investigational Drugs (2008) 17 (5) (741-748)) (2008) (0)
Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. (2012) (0)
Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib. (2019) (0)
Cancer Management Chapter 16: Urothelial and kidney cancers (2010) (0)
Clinical outcomes of patients with metastatic renal cell carcinoma receiving subsequent therapy after progression on front-line immune-VEGF TKI combination therapy (2019) (0)
756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies (2016) (0)
Clinical impact of an online tool to guide choice of therapy (Tx) for patients (Pts) with advanced renal cell carcinoma (RCC). (2013) (0)
Prognostic markers assessment in invasive upper tract urothelial carcinoma (UTUC). (2016) (0)
The impact of facility case volume on overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. (2018) (0)
Issue information (2013) (0)
Kidney Cancer Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma (2015) (0)
Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma. (2021) (0)
The von Hippel Lindau (VHL) gene status is not always identical in paired primary (P) and metastatic (M) lesion in patients with clear cell renal cell carcinoma (CCRCC) (2008) (0)
PBRM1 Loss in Kidney Cancer Unbalances the Kidney Lineage Master Transcription Factor Hub to Repress Terminal Epithelial Fates (2019) (0)
Evaluation of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and pathologic response in urothelial carcinoma (UC). (2016) (0)
Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC). (2017) (0)
MP64-13 NON-METASTATIC RENAL CANCERS OF MODERATE TO HIGH COMPLEXITY ARE AMENABLE TO PARTIAL NEPHRECTOMY AFTER NEOADJUVANT SUNITINIB (2014) (0)
Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. (2013) (0)
V1022 ROBOTIC PARTIAL NEPHRECTOMY FOLLOWING NEOADJUVANT TYROSINE KINASE INHIBITOR TREATMENT (2011) (0)
Association of cell-free DNA (cfDNA) levels with myeloid-derived suppressor cells (MDSC) levels in blood of patients (pts) with muscle invasive (MI) and metastatic (met) bladder cancer (BC). (2019) (0)
Abstract 2505: Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma (2019) (0)
Early Salvage Pelvic Radiation Therapy for Lymph Node–Positive Prostate Cancer Following Prostatectomy (2014) (0)
Correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC). (2016) (0)
Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo). (2018) (0)
Single-Cell VIPER Identifies Recurrence-Associated Renal Tumor Macrophages (2021) (0)
Abstract SY27-03: Biomarker-guided development of novel multi-peptide cancer vaccines - from discovery to phase lll trials. (2013) (0)
Target identification by phosphoproteomics: RIN1 modulation of sorafenib-induced cytotoxicity in renal cell carcinoma. (2009) (0)
Impact of lymph node mets in mRCC. Eur Urol 2015 (2015) (0)
V07-05 ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY WITH INTRACORPOREAL HYPOTHERMIA AFTER PAZOPANIB TREATMENT IN A SOLITARY KIDNEY WITH SEGMENTAL VEIN THROMBOSIS (2018) (0)
Phase I I T rial o f W eekly I ntravenous G emcitabine W ith Continuous I nfusion F luorouracil i n P atients W ith Metastatic R enal C ell C ancer (2000) (0)
T cell infiltration in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC). (2017) (0)
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma (2018) (0)
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (2021) (0)
Abstract 1117: Macrophage migration inhibitory factor (MIF) plays a critical role in clear cell renal carcinoma (2011) (0)
Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC). (2020) (0)
Role of renal cell carcinoma in the induction of neutrophil dedifferentiation into myeloid-derived suppressor-like cells and the expression of immunosuppressive markers (2018) (0)
Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction). (2019) (0)
Immunotherapy in Genitourinary Malignancies (2021) (0)
Correlation between patient-reported fatigue and hemoglobin (Hgb) levels in metastatic renal cell carcinoma (mRCC) patients (pts) receiving sunitinib (SU). (2014) (0)
Evaluation of prognostic factors in upper tract urothelial carcinoma (UTUC). (2016) (0)
Consideration of the number of prostate biopsy samples found to be positive for cancer may add clinically useful information to T stage, Gleason score, and prostate-specific antigen level in predicting outcome after radical prostatectomy. Higher radi- (2001) (0)
906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme (2021) (0)
Genomic testing enhances treatment choices and clinical trial accrual in metastatic colorectal cancer (CRC): Results of a prospective clinical study. (2015) (0)
Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer: Results of a prospective cohort study. (2015) (0)
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). (2021) (0)
Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma (2023) (0)
American Society of Clinical Oncology: Everolimus (RAD001) in renal cell carcinoma (2008) (0)
Poster ViewingMolecular Profiling of Small Cell Bladder Cancer Reveals Gene Expression Determinants of an Aggressive Phenotype (2017) (0)
Immune cell repertoire in patients with indolent metastatic renal cell carcinoma. (2013) (0)
A phase II trial of interferon-alpha and celecoxib in metastatic renal carcinoma: clinical and anti-angiogenic effects. (2004) (0)
Information Transparency in the Drug Approval Process. (2018) (0)
Current and emerging first-line systemic therapies in clear cell renal cell carcinoma. (2018) (0)
Phase II trial of sunitinib as maintenance therapy after stereotactic radiosurgery in patients with one to three newly diagnosed brain metastases. (2010) (0)
Abstract B213: Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib‐refractory metastatic renal cell carcinoma (mRCC) (2009) (0)
Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab. (2022) (0)
Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Response (2011) (0)
LBA01-08 INTERIM ANALYSIS OF PADRES (PRIOR AXITINIB AS A DETERMINANT OF OUTCOME OF RENAL SURGERY NCT03438708) CLINICAL TRIAL (2022) (0)
Sorafenib in Advanced Renal Cancer (2012) (0)
The association between PSA pattern changes and progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone and prednisone (AA/P). (2020) (0)
Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. (2014) (0)
Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC). (2016) (0)
Clinical and Management Implications Associated with Histologic Subtypes of Renal Cell Carcinomas (2015) (0)
Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy. (2019) (0)
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies. (2006) (0)
Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function. (2018) (0)
Challenges with genomic testing in pancreaticobiliary cancers: Results of a prospective cohort study. (2015) (0)
The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC). (2018) (0)
Impact of PSMA-targeted PET/CT in the clinical management of men with advanced prostate cancer. (2022) (0)
Comparative effectiveness of tumor response assessment methods: Standard-of-care versus computer-assisted response evaluation. (2017) (0)
633 Incorporating checkpoint inhibitors into cancer care: a study of the impact of digital education on clinical competence and practice patterns (2021) (0)
Adult UrologyOncology: Adrenal/Renal/Upper Tract/BladderEditorial Comment (2008) (0)
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. (2021) (0)
Erratum: Cessation of vascular endothelial growth factortargeted therapy in patients with metastatic renal cell carcinoma. (Cancer (2012) DOI: 10.1002/cncr.26666) (2012) (0)
Durable complete responses and near complete responses to sunitinib in metastatic renal cell carcinoma (2007) (0)
Racial disparities in the outcomes of transitional cell carcinoma of the bladder: A population-based analysis. (2020) (0)
PD03-10 COMPREHENSIVE MOLECULAR AND GENOMIC CHARACTERIZATION OF PANCREATIC TROPISM IN METASTATIC RENAL CELL CARCINOMA (2019) (0)
Therapeutics , Targets , and Chemical Biology Noncytotoxic Differentiation Treatment of Renal Cell Cancer (2011) (0)
The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies. (2020) (0)
Editorial comment. (2010) (0)
349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 (2021) (0)
VEGF: Biologic Aspects and Clinical Approaches (2009) (0)
Analysis of an online tool to explore evolving practice patterns in renal cell carcinoma (RCC). (2018) (0)
SUN-739 Next Generation AR Antagonists Increase Systemic Active Glucocorticoid Exposure by Altering Glucocorticoid Metabolism (2020) (0)
Mammalian target of rapamycin inhibitors: the beginning of the end or the end of the beginning? (2014) (0)
Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). (2015) (0)
Descriptive comparison of hospital formulary decisions with published oncology valuation methods (2020) (0)
Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual Meeting. (2012) (0)
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study (2019) (0)
Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS). (2021) (0)
Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance). (2021) (0)
PD39-03 HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY GENES PREDICT OVERALL SURVIVAL FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (2020) (0)
Gender impact on renal cell carcinoma survival: A population-based analysis. (2020) (0)
Flow cytometric detection of MDSC populations in unfractionated blood. (2017) (0)
MP78-11 DO SARCOMATOID AND RHABDOID DIFFERENTIATION HAVE SIMILAR PROGNOSTIC EFFECTS FOR PATIENTS WITH GRADE 4 RENAL CELL CARCINOMA? (2016) (0)
294 EFFECT OF PAZOPANIB ON MYELOID DERIVED SUPPRESSOR CELLS AND T CELL FUNCTION IN METASTATIC RENAL CELL CARCINOMA PATIENTS (2013) (0)
Medical Management of Metastatic Renal Cell Carcinoma (2015) (0)
Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years (2018) (0)
Association of tumor burden characteristics with outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. (2009) (0)
Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium. (2012) (0)
Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC). (2023) (0)
Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study. (2021) (0)
The Wolchok/Motzer article reviewed (2000) (0)
Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. (2013) (0)
The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial (2004) (0)
Relapse models for clear cell renal carcinoma - Authors' reply. (2015) (0)
Department of Error (2012) (0)
Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT). (2018) (0)
Phase II trial of intermittent therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with front-line ipilimumab and nivolumab (Ipi/Nivo). (2023) (0)
Review State of the Science : An Update on Renal Cell Carcinoma (2012) (0)
1018: Immunotherapy (APC8015) for Androgen Dependent, Biochemically-Relapsed Prostate Cancer (2005) (0)
Rheumatologic immune-related adverse events (irAE) in patients (pts) with genitourinary (GU) malignancies treated with immune checkpoint inhibitors (CPI). (2018) (0)
response from a randomized phase II study in metastatic renal cell carcinoma (2015) (0)
PD40-09 ASSOCIATION BETWEEN PRIOR NEPHRECTOMY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITOR THERAPY IN METASTATIC RENAL CELL CARCINOMA - A SYSTEMATIC REVIEW AND META-ANALYSIS (2021) (0)
response from a randomized phase II study in metastatic renal cell carcinoma (2015) (0)
1658 METASTASECTOMY FOLLOWING TARGETED THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA (2010) (0)
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events (2020) (0)
Data to decisions: The impact of online education on immunotherapy in advanced renal cell carcinoma. (2020) (0)
Impact of preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival or recurrence free survival in muscle-invasive bladder cancer at cystectomy. (2020) (0)
FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials. (2020) (0)
Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). (2012) (0)
Topical overview New approaches in advanced renal cell carcinoma (2005) (0)
Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC). (2022) (0)
Clinically Useful Biomarkers in Metastatic Renal Cell Carcinoma (2021) (0)
Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial (2016) (0)
6 First and further lines of therapy in clear cell renal cell carcinoma (2011) (0)
Limiting allogeneic bone marrow transplantation based on psychosocial criteria: A comparison of professional attitudes (2005) (0)
Role of quantitative gene expression using RT-PCR in the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC). (2011) (0)
Retrospective analysis of risk factors for fatigue in clinical trial patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (0)
7 Characterizing the impact of lymph node metastases on survival outcome of metastatic renal cell carcinoma patients treated with targeted therapies (2015) (0)
359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinib (2014) (0)
Nonsurgical Management of Metastatic Renal Cell Carcinoma (2008) (0)
A Multicenter Validation Study of Genetic Polymorphisms Associated With Toxicity and Efficacy of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. (2015) (0)
Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial. (2023) (0)
Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS). (2019) (0)
Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma (2009) (0)
Early PSA decline as a predictor of progression in patients with metastatic castration-naïve prostate cancer (mCNPC) treated with abiraterone acetate and prednisone (AA/P). (2020) (0)
The addition of imatinib mesylate to estramustine/docetaxel (E/D) for the treatment of hormone refractory prostate cancer (HRPC) patients: Results of a phase I trial. (2004) (0)
Abstracts: ASCPT 2016 Annual Meeting & Quantitative Translational Approaches in Oncology Pre-Conference. (2016) (0)
Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC). (2018) (0)
1006 ORAL Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC) (2011) (0)
Temsirolimus in VEGF-refractory metastatic renal cell (2011) (0)
Immunotherapy for prostate cancer (2001) (0)
Changing Landscape of Refractory Renal Cell Carcinoma. (2016) (0)
HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism (2017) (0)
Genitourinary oncology referral patterns to the cancer associated thrombosis clinic: The Cleveland Clinic experience. (2020) (0)
A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (0)
SPEAK UP: Itʼs Easier to Target the Tumor than the Patient (2010) (0)
Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes. (2018) (0)
Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors (2021) (0)
Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma. (2019) (0)
Correlation of genomic alterations with outcome in patients (pts) with urothelial carcinoma (UC). (2016) (0)
Evaluation of response to enzalutamide (E) consecutively after disease progression on abiraterone/prednisone (AP) and potential predictors of response. (2016) (0)
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma (2016) (0)
Circulating tumor cells in metastatic castration-resistant prostate cancer (2009) (0)
Third-Generation TKIs (Axitinib, Tivozanib) in RCC: Enhanced Efficacy and Diminished Toxicity? (2015) (0)
Associated with T Cell Dysfunction Cells from Renal Cell Carcinoma Patients Is Elevated Levels of Select Gangliosides in T (2013) (0)
Cytoreductive radical nephrectomy (cRN) and level II-IV infereior vena cava (IVC) thrombectomy for metastatic renal cell carcinoma (mRCC). (2012) (0)
Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib (2017) (0)
Achieving “Zero PSA” Following Post-Prostatectomy Radiation Therapy for Lymph Node Positive Prostate Cancer in the Ultrasensitive PSA Era (2018) (0)
Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts). (2018) (0)
Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC). (2017) (0)
Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium. (2012) (0)
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. (2022) (0)
Clinical outcome of gamma knife (GK) radiotherapy for central nervous system (CNS) metastases from renal cell carcinoma (RCC). (2011) (0)
The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant prostate cancer (CRPC). (2016) (0)
Long-term duration of axitinib treatment in advanced renal cell carcinoma (2016) (0)
7140 POSTER A Randomized Phase 2 Study of Axitinib Dose Titration in Patients With Advanced Renal Cell Carcinoma (RCC): Preliminary Pharmacokinetic and Ambulatory Blood Pressure (BP) Monitoring Results (2011) (0)
Perspectives on under-representation of minority patients (pts) in clinical trials. (2021) (0)
Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. (2013) (0)
The association between the treatment-induced hypertension (Htn) and response to neoadjuvant sunitinib in renal cell carcinoma (RCC). (2012) (0)
Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration. (2019) (0)
Abstract 5599: Soluble PD-L1 as a surrogate biomarker of metastatic progression and resistance to antiangiogenic therapy (2017) (0)
Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’ (2021) (0)
Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. (2016) (0)
Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab. (2020) (0)
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. (2022) (0)
Cytoreductive radical nephrectomy (cRN) and level II-IV infereior vena cava (IVC) thrombectomy for metastatic renal cell carcinoma (mRCC). (2012) (0)
Reply to S. Tan et al. (2022) (0)
1107 Outcomes of patients with non clear cell renal cell carcinoma treated with targeted therapy and prognostication using the International mRCC Database Consortium Criteria (2013) (0)
Myeloid derived suppressor cells (MDSC) correlate with inflammatory biomarkers in metastatic urothelial carcinoma (mUC) (2017) (0)
The impact of marital status on the survival of transitional cell carcinoma of the bladder. (2020) (0)
Editorial comment. (2009) (0)
Is Guillain Barré Syndrome Likely in This Patient (2008) (0)
OP-JNCI200067 1..10 (2020) (0)
Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials. (2018) (0)
Notice of retraction: "Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development" (BJUI, Volume 96, Issue 3, pages 286 – 290). (2012) (0)
Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies. (2013) (0)
Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). (2017) (0)
Immune cell repertoire in patients with metastatic renal cell carcinoma: Data from prospective clinical trial. (2015) (0)
TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial. (2021) (0)
ANZUP Scientific Program and Pre‐Conference Meetings (2015) (0)
Abstract 2572:HSD3B1genotype and abiraterone metabolism in patients with prostate cancer (2018) (0)
C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101. (2023) (0)
Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Brian I. Rini?

Brian I. Rini is affiliated with the following schools:

University of Texas Southwestern Medical Center
Harvard University
University of Calgary
MD Anderson Cancer Center
Wayne State University
University of Chicago
University of Toronto
University of Iowa
University of California, San Francisco
Baylor University
Aarhus University
Medical University of South Carolina
Vanderbilt University
Sumy State University
Stanford University
Case Western Reserve University